{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:30:39Z","timestamp":1793413839494,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014810","name":"Normandie Universit\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014810","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jid.2026.06.1274","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:26:48Z","timestamp":1781800008000},"page":"3044-3053.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Daratumumab as a therapeutic option for rituximab-recalcitrant pemphigus"],"prefix":"10.1016","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4221-2792","authenticated-orcid":false,"given":"Maud","family":"Maho-Vaillant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8967-0913","authenticated-orcid":false,"given":"Alexis","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3532-5345","authenticated-orcid":false,"given":"Marie-Laure","family":"Golinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4358-8417","authenticated-orcid":false,"given":"S\u00e9bastien","family":"Calbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1055-106X","authenticated-orcid":false,"given":"L\u00e9opoldine","family":"Lebourgeois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2887-1863","authenticated-orcid":false,"given":"Marion","family":"Carrette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5391-9745","authenticated-orcid":false,"given":"Fabienne","family":"Jouen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8622-1426","authenticated-orcid":false,"given":"Chlo\u00e9","family":"Challamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3574-5614","authenticated-orcid":false,"given":"Nicolas","family":"Fazilleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0165-5263","authenticated-orcid":false,"given":"Carle","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5734-0255","authenticated-orcid":false,"given":"Pascal","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7404-010X","authenticated-orcid":false,"given":"Billal","family":"Tedbirt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9071-2033","authenticated-orcid":false,"given":"Vivien","family":"H\u00e9bert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2026.06.1274_bib1","doi-asserted-by":"crossref","DOI":"10.1155\/2009\/187864","article-title":"Detection of autoantibodies against recombinant desmoglein 1 and 3 molecules in patients with pemphigus vulgaris: correlation with disease extent at the time of diagnosis and during follow-up","volume":"2009","author":"Belloni-Fortina","year":"2009","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.jid.2026.06.1274_bib2","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.smim.2006.04.003","article-title":"Regulation of B cell self-tolerance by BAFF","volume":"18","author":"Brink","year":"2006","journal-title":"Semin Immunol"},{"key":"10.1016\/j.jid.2026.06.1274_bib3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13075-018-1578-z","article-title":"Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus","volume":"20","author":"Cole","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jid.2026.06.1274_bib4","doi-asserted-by":"crossref","first-page":"175ra30","DOI":"10.1126\/scitranslmed.3005166","article-title":"Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response","volume":"5","author":"Colliou","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jid.2026.06.1274_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.666022","article-title":"Modifications of the BAFF\/BAFF-receptor axis in patients with pemphigus treated with rituximab versus standard corticosteroid regimen","volume":"12","author":"H\u00e9bert","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2026.06.1274_bib6","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/bjd\/ljae220","article-title":"The emergence of circulating activated autoreactive desmoglein 3-specific follicular regulatory T cells is associated with long-term efficacy of rituximab in patients with pemphigus vulgaris","volume":"191","author":"H\u00e9bert","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2026.06.1274_bib7","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/nrrheum.2011.1","article-title":"Long-lived autoreactive plasma cells drive persistent autoimmune inflammation","volume":"7","author":"Hiepe","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jid.2026.06.1274_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003604","article-title":"Daratumumab for autoimmune diseases: a systematic review","volume":"9","author":"Holzer","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.jid.2026.06.1274_bib9","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2026.06.1274_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.26","article-title":"Pemphigus","volume":"3","author":"Kasperkiewicz","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jid.2026.06.1274_bib11","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/ajh.20951","article-title":"The role of autoantibody-producing plasma cells in immune thrombocytopenic purpura refractory to rituximab","volume":"82","author":"Kuwana","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jid.2026.06.1274_bib12","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/jamadermatol.2022.2149","article-title":"Evaluation of clinical relevance and biological effects of Antirituximab antibodies in patients with pemphigus","volume":"158","author":"Lemieux","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2026.06.1274_bib13","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jid.2026.06.1274_bib14","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1016\/j.jid.2021.01.031","article-title":"Rituximab and corticosteroid effect on desmoglein-specific B cells and desmoglein-specific T follicular helper cells in pemphigus","volume":"141","author":"Maho-Vaillant","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2026.06.1274_bib15","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jaut.2012.05.010","article-title":"Bone marrow of NZB\/W mice is the major site for plasma cells resistant to dexamethasone and cyclophosphamide: implications for the treatment of autoimmunity","volume":"39","author":"Mumtaz","year":"2012","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jid.2026.06.1274_bib16","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2026.06.1274_bib17","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with daratumumab in refractory systemic lupus erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jid.2026.06.1274_bib18","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jid.2026.06.1274_bib19","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1001\/jamadermatol.2023.5679","article-title":"Sustained remission without corticosteroids among patients with pemphigus who had rituximab as first-line therapy: follow-up of the ritux 3 trial","volume":"160","author":"Tedbirt","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2026.06.1274_bib20","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.immuni.2004.05.010","article-title":"Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches","volume":"20","author":"Thien","year":"2004","journal-title":"Immunity"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X26026229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X26026229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:53:18Z","timestamp":1793411598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X26026229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0022202X26026229"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2026.06.1274","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Daratumumab as a therapeutic option for rituximab-recalcitrant pemphigus","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2026.06.1274","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}